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Abstract
Objectives
We evaluated the ability of the Fatty Liver Index (FLI), a surrogate marker of hepatic
steatosis, to predict the development of type 2 diabetes (T2D) at 3 years follow-up in a
Spanish cohort with prediabetes from a prospective observational study in primary care
(PREDAPS).
Methods
FLI was calculated at baseline for 1,142 adult subjects with prediabetes attending primary
care centers, and classified into three categories: FLI <30 (no steatosis), FLI 30–60 (inter-
mediate) and FLI60 (hepatic steatosis). We estimated the incidence rate of T2D in each
FLI category at 3 years of follow-up. The association between FLI and incident T2D was cal-
culated using Cox regression models adjusted for age, sex, educational level, family history
of diabetes, lifestyles, hypertension, lipid profile and transaminases.
Results
The proportion of subjects with prediabetes and hepatic steatosis (FLI60) at baseline was
55.7%. The incidence rate of T2D at 3 years follow-up was 1.3, 2.9 and 6.0 per 100 person-
years for FLI<30, FLI 30->60 and FLI60, respectively. The most significant variables
increasing the risk of developing T2D were metabolic syndrome (hazard ratio [HR] = 3.02;
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95% confidence interval [CI] = 2.14–4.26) and FLI60 (HR = 4.52; 95%CI = 2.10–9.72).
Moreover, FLI60 was independently associated with T2D incidence: the HR was 4.97
(95% CI: 2.28–10.80) in the base regression model adjusted by sex, age and educational
level, and 3.21 (95%CI: 1.45–7.09) in the fully adjusted model.
Conclusions
FLI may be considered an easy and valuable early indicator of high risk of incident T2D in
patients with prediabetes attended in primary care, which could allow the adoption of effec-
tive measures needed to prevent and reduce the progression of the disease.
Introduction
Non-alcoholic fatty liver disease (NAFLD) is characterized by free fatty acid and triglyceride
infiltration of hepatocytes that is not the result of significant alcohol intake or secondary to
established liver diseases. It is an entity that encompasses a wide spectrum of lesions ranging
from simple steatosis to steatohepatitis, and can progress to liver cirrhosis or even hepatocellu-
lar carcinoma [1, 2]. The estimated overall worldwide prevalence of NAFLD in the general
adult population is about 25% [3], and increases substantially up to 40%-70% in subjects with
established type 2 diabetes (T2D) [4]. In Spain, the prevalence of NAFLD has been estimated
to be 26% among the adult population [5]. In addition, several epidemiological studies have
consistently shown that NAFLD is an independent risk factor for incident T2D [6], metabolic
syndrome [7], and cardiovascular disease (CVD) [8]. Given the progressive nature of the dis-
ease and the risk of serious consequences, health care providers are strongly advised to screen
for NAFLD in all patients with T2D and to be more proactive in their management [9].
Liver biopsy is the gold standard method to diagnose NAFLD, and as it is quantitative, is
the only one way to distinguish between simple steatosis and steatohepatitis. However, it has
important limitations: it is an invasive procedure that carries an inherent risk to the patient, it
is costly, and it is subject to high interobserver and sampling variability [10]. For these reasons,
non-invasive methods, including imaging techniques or serum markers, are increasingly being
used [11]. Abdominal ultrasound imaging is the method of choice because it is widely available
and inexpensive, but in spite of being sensitive to detect fat accumulation when more than
33% of hepatocytes are steatotic, it does not provide information on the degree of fibrosis [11].
Furthermore, single serological markers are suboptimal for diagnosing NAFLD. Therefore,
different models that combine multiple clinical and biochemical parameters have been pro-
posed: these indices are easily obtained in routine clinical practice, are readily applicable, and
some have shown good diagnostic accuracy for detecting steatosis [11, 12]. The Fatty Liver
Index (FLI) is a simple algorithm that combines measures of triglycerides, gamma glutamyl-
transpeptidase (GGT), waist circumference and body mass index (BMI). FLI has an excellent
discriminative ability to predict ultrasonographic fatty liver disease [13], and has been vali-
dated in both Asian and Western populations [14, 15]. FLI has been reported to correlate with
insulin resistance, risk of coronary heart disease, risk of metabolic syndrome, early atheroscle-
rosis, and rates of non-hepatic-related morbidity and mortality in nondiabetic subjects [16–
19]. Finally, FLI also predicts incident hypertension in normotensive individuals [20], and fur-
ther metabolic deterioration in women with previous gestational diabetes [21].
Two meta-analyses have reported that NAFLD diagnosed by either altered serum liver
enzymes, radiological, or histological evidence increases the risk of developing T2D [7, 22],
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and FLI-diagnosed NAFLD has also been found to be a good predictor of incident T2D [23–
26]. In addition, different studies have reported that ultrasonography-diagnosed NAFLD pre-
dicts the occurrence of prediabetes [27–31]. However, the risk of progression to T2D in sub-
jects with prediabetes has not been studied at large, and all available studies so far have been
conducted in Asian populations: two of them used ultrasonography to diagnose NAFLD [28,
32], and only one used FLI [33]. The possibility of using FLI in subjects with prediabetes is of
great interest because, based on epidemiological and clinical evidence, people at increased risk
of developing T2D should be the target of primary prevention efforts [34]. The objective of the
present study was to determine the FLI’s ability to predict the development of T2D in a pri-
mary care European population with prediabetes.
Materials and methods
Study design and data source
This was a follow-up study of a cohort of 1,184 subjects with prediabetes and another cohort of
838 subjects without alterations in glucose metabolism participating in the PREDAPS (Pri-
mary Health Care on the Evolution of Patients with Prediabetes) Study [35]. Briefly, the PRE-
DAPS is a prospective observational study that collected baseline data from patients aged 30–
74 years attending primary care centers in Spain throughout 2012 that are currently under fol-
low-up to 5 years. Patients were excluded if they had any of the following conditions: diabetes,
terminal disease, pregnancy, major surgery or hospital admission in the preceding 3 months,
or hematological diseases that could interfere with the HbA1c value.
Prediabetes was defined using the American Association of Diabetes criteria for prediabetes
[36], namely fasting plasma glucose (FPG) levels between 100 and 125 mg/dl and/or HbA1c
between 5.7% and 6.4% (39 and 46 mmol/mol) in the prior 6 months. Recruited subjects were
subsequently monitored annually to determine the incidence of new cases of T2D, defined as
basal plasma glucose level126 mg/dl on two occasions, or HbA1c6.5% (48 mmol/mol)
on two occasions, or both at the same time [36].
The present study analyzed the relationship between FLI and various clinical and socio-
demographic characteristics measured at baseline and the onset of T2D up to the third year
of follow-up among the cohort of subjects with prediabetes and available information
(N = 1,142).
Measures
Detailed information on the methodology of the study has been described elsewhere [35].
Clinical and demographic variables at baseline for this substudy included: age; sex; educational
level; family history of diabetes; smoking status (classified as active smokers, ex-smokers, and
never smokers), alcohol consumption (considering low-risk an intake20 g/day in women
and40 g/day in men), physical activity (frequency and minutes per routine in the prior 2
weeks), sedentary lifestyle, defined as not following the World Health Organization recom-
mendations on physical activity (i.e., at least 150 minutes a week of moderate aerobic activity,
or 75 minutes a week of vigorous aerobic, or an equivalent combination of moderate and vig-
orous activities); and diet, based on the data collected on the frequency of consumption of
fruits and vegetables, where subjects were classified into those who consumed those foods
daily, and those who consumed them less frequently. Likewise, subjects were asked what they
usually had for breakfast, and were divided into those who did not have breakfast or had an
incomplete meal (only coffee, milk, chocolate, cocoa or yogurt), and those who had a proper
breakfast.
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During physical examination, height, weight, waist circumference and blood pressure were
measured. Patients were classified with general obesity if their BMI was30 kg/m2 and with
abdominal obesity if waist circumference was102 cm in men and88 cm in women. Hyper-
tension was defined as systolic blood pressure (SBP)140 mmHg, diastolic blood pressure (DBP)
90 mmHg, currently taking antihypertensive drugs or personal history of high blood pressure.
The following 12-hour fasting plasma determinations were measured: FPG, HbA1c, lipid
profile (total cholesterol [TC], high-density lipoprotein [HDL], low-density lipoprotein [LDL]
and triglycerides [TG]), GGT and transaminases (aspartate transaminase [AST] and alanine
transaminase [ALT]). Hypercholesterolemia was defined as total serum cholesterol250 mg/
dL, low HDL as<40 mg/dL in men and<50 mg/dL in women, high LDL100 mg/dL, and
hypertriglyceridemia as serum TG150 mg/dL. Liver enzymes were considered elevated
when GGT40 U/L, or either AST or ALT35 U/L. Subjects were considered to have meta-
bolic syndrome when they met three or more of the following criteria: waist circumference
>102 cm in men or >88 cm in women; TG150 mg/dl; blood pressure130/85 mmHg;
HDL <40 mg/dl in men or <50 mg/dl in women; and FPG between 110 and 126 mg/dL [37].
The FLI as an indicator of hepatic steatosis was calculated based on the measures of TG,
GGT, BMI and waist circumference, using the formula described in the literature [13]. More-
over, and as it has been established, FLI values (ranging from 0 to 100) were classified into
three categories: <30, 30–59, and60 [13]. FLI values of<30 and60 would rule out and
confirm the presence of hepatic steatosis, respectively.
The study was approved by the Ethics Committee of Institut Hospital del Mar. All patient
records and information was anonymized and de-identified prior to analysis.
Statistical analysis
We estimated the percentage and distribution of qualitative characteristics, and the mean of
the quantitative characteristics for the three categories of FLI. Statistical significance was evalu-
ated in the first case using the Chi-square test of heterogeneity, and in the second case with the
analysis of variance (ANOVA) to test for differences between means. We calculated the inci-
dence rate of diabetes per 100 person-years in each FLI category and then evaluated the associ-
ation of the different baseline patient characteristics with the incidence of T2D. The measure
of association was the hazard ratio (HR) and 95% confidence interval (CI) calculated by Cox
regression models. We also estimated the degree to which the characteristics analyzed
explained the association between FLI and the incidence of T2D. We first estimated a base
model adjusted for age, sex and educational level, and then added the different characteristics
to the baseline model, namely family history of diabetes, lifestyles, hypertension, lipid profile
and transaminases. We did not include the variables involved in calculating the FLI (TG,
GGT, BMI, and waist circumference). Patients who died (1.4%) and those who could not be
followed up for 3 years (18.0%) were censored in the analysis, therefore they only contributed
to the risk up to the date of death or loss to follow-up. We also conducted a sensitivity analysis
excluding subjects with high-risk alcohol consumption. Finally, the extent to which FLI may
be a better predictor of diabetes than insulin resistance is of interest. In the present study, fast-
ing plasma insulin was not measured, although we estimated the predictive capacity of several
surrogate markers that have shown high sensitivity and specificity for recognizing insulin
resistance [38–45]. In particular, we analyzed the triglyceride glucose (TyG) index and various
lipid ratios, namely the TG/HDL ratio, the total TC/HDL ratio, and the LDL/HDL ratio. Based
on the value of each of these surrogate markers, subjects were stratified into tertiles. Statistical
significance was established at a p-value <0.05. All analyses were conducted using the SPSS
statistical package (version 20, SPSS, Chicago, Illinois, USA).
FLI as a predictor of diabetes
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Results
Table 1 shows the sociodemographic and clinical characteristics collected at baseline accord-
ing to FLI category. The proportion of subjects with prediabetes and hepatic steatosis (FLI
Table 1. Sociodemographic, lifestyle, and clinical characteristics of subjects with prediabetes at baseline, according to baseline FLI.
Fatty Liver Index
<30 30–59 60 P-value
N (%) 187 (16.4) 319 (27.9) 636 (55.7)
Gender, %
Men 19.8 51.1 58.8 <0.001
Women 80.2 48.9 41.2
Age, years, %
30–49 16.0 12.2 17.1 0.020
50–64 57.8 48.9 48.0
65–74 26.2 38.9 34.9
Educational level, %
Less than secondary 58.8 67.4 64.0 0.15
Secondary or higher 41.2 32.6 36.0
Family history of diabetes, % 44.9 48.6 46.5 0.71
Smoking status, %
Active smoker 15.0 12.5 19.3 <0.001
Ex-smoker 28.3 37.9 42.0
Never smoked 56.7 49.5 38.7
Alcohol consumption, %
None 42.7 35.1 30.2 0.003
Low risk 48.1 55.2 54.3
High risk or harmful 9.2 9.7 15.6
Alcohol consumption (g/day), mean (SD) 9.0 (24.3) 13.1 (34) 20.4 (50.7) 0.002
Diet, %
Daily consumption of fruits 84.5 78.1 75.8 0.04
Daily consumption of vegetables 65.8 58.0 53.9 0.015
Complete breakfast 89.8 87.1 85.2 0.25
Regular physical activity, % 58.3 61.4 51.1 0.007
Metabolic syndrome, % 8.6 21.0 56.3 <0.001
BMI (kg/m2), mean (SD) 24.5 (2.4) 27.5 (2.3) 32.6 (4.2) <0.001
Waist circumference (cm), mean (SD) 84.6 (7.3) 94.8 (6.4) 107.3 (9.6) <0.001
FPG (mg/dL), mean (SD) 101.5 (11.7) 104.7 (10.7) 106.8 (9.9) <0.001
HbA1c (%), mean (SD) 5.8 (0.3) 5.8 (0.3) 5.9 (0,3) 0.003
SBP (mmHg), mean (SD) 127.9 (14.8) 132.7 (14.7) 137.7 (16.3) <0.001
DBP (mmHg), mean (SD) 77.0 (8.6) 79.7 (8.6) 82.9 (9.4) <0.001
AST (U/L), mean (SD) 20.5 (7.4) 22.8 (9.3) 25.3 (11.3) <0.001
ALT (U/L), mean (SD) 20.4 (9.6) 24.4 (11.3) 30.8 (18.0) <0.001
GGT (U/L), mean (SD) 18.5 (8.6) 26.5 (14.8) 44.7 (41.3) <0.001
Total cholesterol (mg/dL), mean (SD) 212.9 (35.6) 209.3 (39.7) 208.8 (37.6) 0.41
HDL cholesterol (mg/dL), mean (SD) 63.2 (16.1) 56.2 (13.2) 50.6 (13.0) <0.001
LDL cholesterol (mg/dL), mean (SD) 132.8 (32.9) 129.7 (35.5) 126.9 (34.1) 0.10
Triglycerides (mg/dL), mean (SD) 85.2 (30.7) 117 (45.9) 156.4 (83.1) <0.001
ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GGT, gamma
glutamyltranspeptidase; HDL, high density lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure; SD, standard deviation
https://doi.org/10.1371/journal.pone.0198327.t001
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60), intermediate FLI (30–59), and no steatosis (FLI <30) was 55.7%, 27.9% and 16.4%,
respectively. Subjects with FLI60 were more frequently men, active smokers and high-risk
drinkers, less frequently consumed fruits and vegetables daily, and exercised less regularly.
Moreover, the frequency of metabolic syndrome was significantly higher in subjects with FLI
60 than in the other groups (56.3% vs. 8.6% in FLI < 30 and 21% in FLI 30–59; p<0.001),
they also had higher rates of unfavorable body composition (higher BMI and waist circumfer-
ence; p<0.001), adverse lipid profile (higher levels of TG and lower values of HDL cholesterol;
p<0.001), and also higher blood pressure than the other FLI groups (p<0.001). Finally, sub-
jects with FLI60 also had higher glycemic levels (FPG and HbA1c; p<0.001 and p = 0.003,
respectively), and their liver enzymes were more elevated than in the other groups (ALT, AST,
and GGT; p<0.001).
Incidence of diabetes over 3 years and associated risk factors
Subjects were followed during an average of 2.83 years (SD = 0.87), and 107 out of the 1,142
initially assessed (9.4%) developed T2D at the end of follow-up. By FLI category, the propor-
tion of participants who developed T2D was the highest among those with FLI60 (n = 107;
16.8%), followed by those with FLI 30–59 (n = 27; 8.5%) and those with FLI <30 (n = 7; 3.7%).
This corresponded to a T2D incidence rate of 1.3, 2.9 and 6.0 per 100 person-years in the cate-
gories FLI<30, FLI 30–59 and FLI60, respectively.
Among all sociodemographic and lifestyle variables, only family history of T2D was found
as a significant risk factor for incident diabetes, while daily consumption of fruit was the only
significant protective factor (Table 2). Regarding clinical and biochemical parameters, the
most significant variables increasing the risk of developing T2D were metabolic syndrome
(HR = 3.02; 95%CI = 2.14–4.26) and FLI60 (HR = 4.52; 95%CI = 2.10–9.72). Other individ-
ual risk factors moderately increasing the likelihood of progression were general obesity based
on BMI, abdominal obesity based on waist circumference, presence of hypertension, high tri-
glycerides, and elevated liver enzymes. Conversely, high levels of HDL cholesterol were protec-
tive against incident T2D.
FLI for the prediction of incident T2D in prediabetes
Multivariate models for the development of T2D at 3 years of follow-up in patients with predi-
abetes (Table 3) showed that the presence of FLI60 was in all cases a significant independent
risk factor. In the base model, adjusted for age, sex and educational level, the HR in the cate-
gory FLI60 with respect to FLI <30 was 4.97 (95%CI = 2.28–10.80). When the baseline
model was adjusted by five other characteristics separately, the HR decreased slightly (HRs
between 4.13 and 4.82). Adjustment for all the variables combined decreased the magnitude of
the HR to 3.21 (95%CI = 1.45–7.09). In the sensitivity analysis restricted to subjects without
high-risk alcohol consumption, the magnitude of the association increased: the HR for FLI
60 was 5.09 (95%CI = 2.20–11.76) in the base model, and 3.54 (95%CI = 1.51–8.31) in the
fully adjusted model.
Finally, Table 4 shows the findings on the models for the risk of development of T2D at 3
years of follow-up in patients with prediabetes according to tertiles of surrogate markers for
insulin resistance. After adjusting for all variables, the magnitude of the hazard ratios for all
markers was lower than that observed with FLI.
Discussion
The results of the present prospective study conducted in Spain in a cohort of patients with
prediabetes (PREDAPS study) showed that FLI-diagnosed hepatic steatosis is associated with a
FLI as a predictor of diabetes
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Table 2. Bivariate analysis of baseline characteristics and incidence of diabetes in patients with prediabetes at 3
years follow-up.






50–64 years 0.93 (0.58–1.47)
65–74 years 0.94 (0.58–1.54)
Educational level
Less than secondary 1.00
Secondary or higher 0.88 (0.62–1.25)






Never smoker 1.16 (0.69–1.95)
Alcohol consumption
None 1.00
Low risk 0.74 (0.52–1.07)
High risk or harmful 0.85 (0.51–1.43)
Daily consumption of fruits
No 1.00
Yes 0.57 (0.40–0.81)













<88 cm (women)/ <102 cm (men) 1.00






AST >35 2.18 (1.39–3.41)
ALT35 1.00
(Continued)
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risk of developing T2D at 3 years of follow-up. Moreover, this association was independent of
possible confounding factors such as family history of diabetes, lifestyle, hypertension, lipid
profile and level of transaminases. The only available study performed so far to assess the inci-
dence of T2D in subjects with prediabetes and NAFLD diagnosed through FLI was performed
in a Japanese population [33]. However, new T2D was diagnosed based on self-administered
questionnaires, and it is not clear whether the results could be as well applied to Western or
Caucasian populations [33]. In our study, the diagnosis of T2D was based on basal plasma glu-
cose or HbA1c values, and it is the first study evaluating the ability of the FLI to predict diabe-
tes in subjects with prediabetes according to ADA criteria [36].
In the PREDAPS study, the baseline prevalence of hepatic steatosis (i.e., FLI60) was 56%,
which is higher than the 19% reported in the Japanese study [33], closer to the approximately
22–40% reported by studies with ultrasonography-diagnosed NAFLD [27, 28, 30, 46–49], and
lower than the 75% observed in overweight and obese subjects in a study using magnetic reso-
nance (MR) [50].
In a previous study conducted in France in subjects from the general population, the
authors found that FLI70 was associated with the development of T2D [23]. Our study
shows that an FLI60 can be a good predictor of T2D in subjects with impaired glucose
metabolism. An important observation in the present study was that patients with FLI60
had the most altered metabolic profile, with a high prevalence of metabolic syndrome and
high values of each of its constituent components. These results are in line with the study of
Nishi et al. conducted in Japanese subjects with prediabetes [33] and also with those of a large
population-based study conducted in Italy in patients with established T2D [51]. These find-
ings are not surprising if we take into account that the degree of liver fat content correlates
Table 2. (Continued)
Variable HR (95%) CI)
ALT >35 1.93 (1.34–2.76)
GGT40 1.00
GGT >40 1.66 (1.18–2.35)
Lipid profile (mg/dL)
Total cholesterol <250 1.00
Total cholesterol250 0.85 (0.51–1.42)
HDL cholesterol <40 (men)/ <50 (women) 1.00
HDL cholesterol 40 (men)/50 (women) 0.58 (0.41–0.82)
LDL cholesterol <100 1.00










ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; CI, confidence interval; DBP,
diastolic blood pressure; FPG, fasting plasma glucose; GGT, gamma glutamyltranspeptidase; HDL, high density
lipoprotein; HR, hazard ratio; LDL, low density lipoprotein; SBP, systolic blood pressure
https://doi.org/10.1371/journal.pone.0198327.t002
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with all components of metabolic syndrome [52]. This correlation can be attributed to the fact
that both NAFLD and T2D share a series of common physiopathological mechanisms, includ-
ing alterations in glucose and lipid metabolism, insulin resistance, and environmental and
genetic factors [51, 53].
Another interesting finding was that patients with FLI60 had significantly higher mean
levels of transaminases than the lower FLI groups, although over half of them exhibited normal
values. It has been previously reported that a substantial number of patients with NAFLD,
even in those with a more advanced stage of the disease, have normal transaminases [54–56].
This is important, since clinicians often rely on abnormal transaminases to identify patients
with NAFLD, but it has been shown that an increase, even when levels are within the normal
range, is an independent predictor of incident T2D and metabolic syndrome [57–59].
Only two previous studies conducted in Asian populations have assessed the risk of pro-
gression to T2D from prediabetes using ultrasonography to diagnose NAFLD. In one prospec-
tive study conducted in Japan, prediabetes was found as the strongest predictor for the
development of T2D at 10-years follow-up, with a 6.4 fold-risk compared with subjects with
normal glucose [28]. In another study, conducted in Korea, the risk for incident T2D at 5
years follow-up was enhanced by 9-fold only in subjects with NAFLD and concomitant
impaired fasting glucose, but no increased risk of T2D was observed among those with
NAFLD and normal glucose [30]. In our study, 9.4% of patients with prediabetes progressed to
T2D during the 3-years follow-up, and the risk of progression was 3.21 times higher for sub-
jects with FLI60 than in those with FLI<30 in the fully adjusted model. This is in agreement
Table 3. Hazard ratios and 95% confidence intervals of multivariate models for the risk of incident T2D in
patients with prediabetes at 3 years of follow-up according to FLI categories.
Fatty Liver Index
<30 30–59 60




























Base model adjusted for family history of T2D, lifestyle hypertension, lipids
and transaminases












Includes tobacco consumption, alcohol intake, consumption of fruits and vegetables, breakfast and physical activity
T2D, type 2 diabetes mellitus; ALT, alanine transaminase; AST, aspartate transaminase; HDL, high density
lipoprotein
https://doi.org/10.1371/journal.pone.0198327.t003
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with the results obtained in the only available and comparable study using FLI to diagnose
NAFLD [33]. In the Nishi et al. Japanese study [33], 11.5% of men and 6% of women with pre-
diabetes developed T2D during 3 years follow-up, and they observed similar risk figures after
adjusting for almost the same variables as in our case (odds ratio 2.68 in men and 10.35 in
women), although in our study the magnitude of HR was lower (1.70 in men and 4.95 in
women).
FLI could be of use in routine clinical practice as an additional screening tool to identify
those with prediabetes at high risk of progression that would benefit from early interventions
[9, 60]. For instance, weight loss via energy restriction or physical activity have been shown to
reduce liver fat and improve hepatic glucose metabolism within weeks [61, 62], and the resolu-
tion of fatty liver to significantly reduce the risk of T2D development to a level similar to indi-
viduals without NAFLD [63, 64]. Moreover, diabetes is an independent factor of NAFLD
progression and of the development of cirrhosis [65–67], and a recent study showed that lipid-
lowering therapy with statins correlates with improvement in the FLI score [19], and another
one that long-term pioglitazone treatment in patients with prediabetes or T2D led to marked
histologic improvements in hepatic steatosis, inflammation, and ballooning without worsening
fibrosis [68]. Finally, NAFLD is an independent risk factor for the development of micro and
macrovascular complications in patients with diabetes [69, 70], and statins have also been
shown to substantially reduce cardiovascular morbidity and mortality by >50% compared
with high-risk patients with normal liver structure and function [71].
The present study has both strengths and limitations that should be acknowledged. Among
its strengths is its prospective design, which included measurement of a large variety of possi-
ble confounding factors. However, given the complex bidirectionality between NAFLD, insu-
lin resistance and hyperglycemia, it is challenging to distinguish whether NAFLD is a cause or
Table 4. Hazard ratios and 95% confidence intervals for the risk of incident T2D in patients with prediabetes at 3 years of follow-up according to tertiles of surro-
gate markers of insulin resistance.
Surrogate markers of insulin resistance Bivariate analysis Multivariate analysis1
HR 95% CI HR 95% CI
TyG Index
1st tertile 1.00 1.00
2nd tertile 1.24 0.71 2.16 1.00 0.56 1.78
3rd tertile 2.44 1.47 4.05 1.87 1.09 3.21
TG/HDL Ratio
1st tertile 1.00 1.00
2nd tertile 1.35 0.83 2.17 1.10 0.66 1.82
3rd tertile 1.95 1.25 3.04 1.59 0.94 2.68
TC/HDL Ratio
1st tertile 1.00 1.00
2nd tertile 1.40 0.89 2.20 1.26 0.78 2.02
3rd tertile 1.73 1.13 2.66 1.40 0.82 2.37
LDL/HDL Ratio
1st tertile 1.00 1.00
2nd tertile 1.20 0.78 1.85 1.07 0.69 1.68
3rd tertile 1.36 0.90 2.06 1.13 0.69 1.83
1Adjusted for age, sex and educational level, family history of T2D, tobacco consumption, alcohol intake, consumption of fruits and vegetables, breakfast and physical
activity, hypertension, lipids and transaminases.
CI, confidence interval; HDL, high density lipoprotein; HR, hazard ratio; LDL, low density lipoprotein; TC, total cholesterol; triglyceride glucose index (TyG index)
https://doi.org/10.1371/journal.pone.0198327.t004
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a consequence of insulin resistance and T2D. With regard to limitations, it must be noted that
the different parameters that make up the FLI are also risk factors for T2D, which could call
into question whether NAFLD based on the FLI is an independent predictor for the presence
of T2D.
Another limitation was that we diagnosed NAFLD with FLI instead of liver biopsy. On the
one hand, FLI was found to be highly reliable in a European study when subsequently con-
firmed by abdominal ultrasound [15], although another population study, where the diagnosis
was confirmed by magnetic resonance spectroscopy, found a more moderate diagnostic preci-
sion [12]. On the other hand, FLI does not give information on the severity of hepatic steatosis,
and we could not assess whether the presence of more severe forms of the disease (i.e., fatty
infiltration plus inflammation [NASH]) appears to afford a greater risk for incident T2D than
simple steatosis, as previously described [72]. Moreover, patients with FLI60 were more
likely to report high-risk alcohol, and GGT, an analytical marker of alcohol consumption, was
also higher than in the lower FLI groups. It is known that alcohol consumption, regardless of
the amount, can cause hepatic steatosis. Thus, although we cannot rule out a possible classifica-
tion bias, whereby fatty liver in some patients classified as having NAFLD was actually due to
alcohol consumption, the results were unchanged when subjects with high-risk alcohol intake
were excluded from the analysis. In addition, we relied on FPG and/or HbA1c to diagnose dia-
betes and prediabetes, and the lack of a 2-hour oral glucose tolerance test might have resulted
in the inclusion of subjects with undiagnosed diabetes at baseline or underestimated the num-
ber of patients with incident T2D cases. Lastly, a potential weakness of the study is that we had
no data on insulin resistance (i.e., HOMA-IR index or fasting insulin), which is strongly asso-
ciated with NAFLD and may contribute to the development of T2D [32, 73]. However, we
were instead able to calculate several surrogate markers of insulin resistance. The magnitude
of HR that evaluated the relationship between these markers and development of T2D at 3
years of follow-up was lower than that the one obtained in subjects whose FLI was60. On
the other hand, although high values of FLI are associated with reduced insulin sensitivity [17,
26], fatty liver diagnosed as FLI60 has been shown to be a predictor of incident diabetes
independently of insulin resistance [24]. In addition, insulin resistance did not significantly
contribute to reduce the risk when it was considered as a confounding factor [23, 26].
Conclusions
FLI should be considered an easy and valuable tool to be used in primary care routine clinical
practice for early identification of significant liver disease in subjects with prediabetes and to
stratify the risk of developing T2D. This way, those at the greatest risk could be carefully moni-
tored so that effective interventions to prevent and reduce progression of the disease could be
adopted.
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Investigation: Llorenç Caballeria, Didac Mauricio.
Project administration: Josep Franch-Nadal.
Supervision: Josep Franch-Nadal, Enrique Regidor.
Writing – original draft: Josep Franch-Nadal, Llorenç Caballeria, Manel Mata-Cases, Didac
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